1-(4-fluorophenyl)-3-methylpyrazole-4-carboxylic acid | 288251-56-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-fluorophenyl)-3-methylpyrazole-4-carboxylic acid
• 英文别名: 1-(4-fluorophenyl)-3-methyl-1H-pyrazole-4-carboxylic acid
• CAS: 288251-56-9
• 化学式: C₁₁H₉FN₂O₂
• mdl: MFCD09965787
• 分子量: 220.203
• InChiKey: AUJMRONEMHYYBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(4-fluorophenyl)-3-methylpyrazole-4-carboxylic acid 在 氯化亚砜 作用下， 以 吡啶 为溶剂， 反应 1.5h， 生成 N-(3-cyano-4-(4-tert-butyldimethylsilyloxypiperidin-1-yl)phenyl)-1-(4-fluorophenyl)-3-methylpyrazole-4-carboxamide
  参考文献：
  名称：

  AMIDE COMPOUNDS AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1176140B1
• 作为产物：
  描述：

  ethyl 2-cyano-3-ethoxybut-2-enoate 在 sodium hydroxide 、 亚硝酸异戊酯 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 7.0h， 生成 1-(4-fluorophenyl)-3-methylpyrazole-4-carboxylic acid
  参考文献：
  名称：

  AMIDE COMPOUNDS AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1176140B1

文献信息

• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2020227101A1

  公开（公告）日：2020-11-12

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因（例如KCNT1）中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因如KCNT1中的功能增强突变的方法。
• Amide compounds and medicinal use thereof
  申请人：Mitsubishi Pharma Corporation

  公开号：US07015218B1

  公开（公告）日：2006-03-21

  The present invention relates to a compound of the formula wherein R1 is substituted aryl, heteroaryl and the like, R2 and R3 are hydrogen, alkyl, halogen, hydroxyl group and the like, Q is N, CH and the like, W is hydrogen, alkyl, hydroxycarbonylalkyl and the like, X is halogen, cyano, nitro, amino and the like, X′ is hydrogen, halogen, cyano, nitro, and Y is alkyl, hydroxyl group, alkoxy, mercapto and the like and a salt thereof, and a medicine containing the said compound. The compound of the present invention shows a superior inhibitory effect on activated lymphocytes proliferation and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

  本发明涉及一种化合物，其化学式为其中R1为取代芳基，杂环芳基等，R2和R3为氢，烷基，卤素，羟基等，Q为N，CH等，W为氢，烷基，羟基羧基烷基等，X为卤素，氰基，硝基，氨基等，X'为氢，卤素，氰基，硝基，Y为烷基，羟基，烷氧基，巯基等及其盐，以及包含所述化合物的药物。本发明的化合物显示出对活化淋巴细胞增殖的优越抑制作用，并可用作各种自身免疫性疾病的预防或治疗剂。
• <i>N</i>-Arylpyrazole NOD2 Agonists Promote Immune Checkpoint Inhibitor Therapy
  作者：Matthew E. Griffin、Taku Tsukidate、Howard C. Hang

  DOI：10.1021/acschembio.3c00085

  日期：2023.6.16
• KCNT1 INHIBITORS AND METHODS OF USE
  申请人：Praxis Precision Medicines, Inc.

  公开号：EP3962481A1

  公开（公告）日：2022-03-09
• HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE
  申请人：Rodin Therapeutics, Inc.

  公开号：US20180194769A1

  公开（公告）日：2018-07-12

  This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.